文献速递甲状腺疾病

索拉非尼治疗碘难治性分化型甲状腺癌的真实世界延长观察及仑伐替尼挽救治疗的影响:韩国多中心研究

Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
PubMed 文献 · Thyroid · 2019-10-08

本研究为韩国多中心回顾性队列研究的延长分析,纳入98例进展性放射性碘难治性分化型甲状腺癌患者,评估一线索拉非尼的疗效及仑伐替尼挽救治疗的价值。结果显示索拉非尼中位总生存期41.5个月,无疾病相关症状者生存更优,而一线进展后接受仑伐替尼挽救治疗可显著改善总生存。

要点

  • 索拉非尼治疗98例患者的中位OS为41.5个月,中位PFS为13.5个月
  • 治疗前无疾病相关症状者OS更优(HR 0.56,95%CI 0.31-0.99,p=0.048)
  • 索拉非尼进展后仑伐替尼挽救治疗显著改善OS(HR 0.28,95%CI 0.15-0.53,p<0.001)

核心结论

  • 索拉非尼治疗进展性RAI难治性DTC患者的中位OS为41.5个月,中位PFS为13.5个月。
  • 治疗前无疾病相关症状及较小肿瘤负荷与一线索拉非尼的生存获益相关。
  • 一线索拉非尼进展后使用仑伐替尼挽救治疗可显著改善OS。

研究设计与样本

  • 本研究为既往多中心、回顾性队列研究的延长研究,纳入98例接受索拉非尼治疗的进展性RAI难治性DTC患者。
  • 主要终点为总生存期(OS)。
  • 挽救治疗分析比较32例接受仑伐替尼治疗与41例未接受挽救治疗的患者。

主要发现

  • 全部98例患者的中位OS为41.5个月,中位PFS为13.5个月。
  • 治疗前无疾病相关症状者OS优于有症状者(HR=0.56,95%CI 0.31-0.99,p=0.048)。
  • 肿瘤体积较大与死亡风险轻微增加相关(HR=1.02,95%CI 1.00-1.03,p=0.049)。
  • 最佳肿瘤反应与OS无关(p=0.490)。
  • 仑伐替尼挽救治疗组OS显著优于未挽救组(HR=0.28,95%CI 0.15-0.53,p<0.001)。

关键数值与推荐

  • 索拉非尼一线治疗后疾病进展起,未接受挽救治疗组中位OS为4.9个月。
  • 仑伐替尼挽救治疗组自一线索拉非尼进展起的中位OS未达到。
  • 治疗前无疾病相关症状者对比有症状者:HR=0.56(95%CI 0.31-0.99,p=0.048)。
  • 肿瘤大小与死亡风险:HR=1.02(95%CI 1.00-1.03,p=0.049)。
  • 仑伐替尼挽救治疗对比未挽救:HR=0.28(95%CI 0.15-0.53,p<0.001)。

临床怎么用

  • 对进展性RAI难治性DTC,可考虑索拉非尼作为一线靶向治疗。
  • 治疗前评估疾病相关症状与肿瘤负荷,有助于预判索拉非尼生存获益。
  • 一线索拉非尼进展后,及时评估并启用仑伐替尼挽救治疗可能改善生存。

局限性

  • 本研究为回顾性研究,存在选择偏倚等固有局限。
  • 挽救治疗分析中仑伐替尼组与未挽救组样本量有限(32例与41例)。
  • 为单国多中心真实世界数据,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Treatment for patients with radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC) is challenging. Recently, two tyrosine kinase inhibitors (sorafenib and lenvatinib) have been approved and showed benefits for progression-free survival with tolerable adverse events. Methods: This is an extension study of a previous multicenter, retrospective cohort study of real-world experience in treating 98 patients with progressive RAI-refractory DTC with sorafenib. The primary endpoint was overall survival (OS). The efficacy of lenvatinib as salvage therapy after disease progression on first-line sorafenib was evaluated by comparing outcomes in 32 patients who were treated with lenvatinib with 41 patients who were not and therefore served as a no salvage treatment group. Results: The median OS of all 98 patients treated with sorafenib was 41.5 months, and the median progression-free survival was 13.5 months. Patients without disease-related symptoms before sorafenib treatment had better OS than those with symptoms (hazard ratio [HR] = 0.56 [95% confidence interval, CI 0.31-0.99], p = 0.048). Larger tumor size was associated with a minimally increased risk of death (HR = 1.02 [CI 1.00-1.03], p = 0.049). Best tumor response was not associated with OS (p = 0.490). Lenvatinib salvage treatment significantly improved OS in patients receiving it compared with those who did not (HR = 0.28 [CI 0.15-0.53], p < 0.001). The median OS from the time of disease progression after first-line sorafenib treatment was 4.9 months in no salvage treatment group, whereas it was not reached in the lenvatinib salvage group. Conclusions: The absence of disease-related symptoms and smaller tumor burden was associated with survival benefits of first-line sorafenib treatment in patients with progressive RAI-refractory DTC. Lenvatinib salvage therapy was effective in improving OS in patients with disease progression after first-line sorafenib.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Oh HS, Shin DY, Kim M, et al. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. Thyroid. 2019. PMID: 31592739. doi:10.1089/thy.2019.0246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。